Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05766306
Other study ID # L-024
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 15, 2023
Est. completion date February 2, 2024

Study information

Verified date August 2023
Source Lallemand Health Solutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test to efficacy of a probiotic blend on stress in adolescents with moderate perceived stress. It is hypothesized that those taking the probiotic blend will have decreased levels of stress compared to those receiving the placebo.


Description:

Participants in this randomized, double-blind, placebo-controlled, parallel study will be adolescents with moderate perceived stress. Participants will be enrolled in this study for 63 days, with a 56-day intervention period and a 7 day follow-up period. There will be a total of 5 visits: 4 in-person and 1 follow-up phone call.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2, 2024
Est. primary completion date February 2, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria: 1. Males and females between 13 and 17 years, inclusive 2. Individuals of child-bearing potential must have a negative screening urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: - Abstinence or agrees to use contraception if planning to become sexually active - Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) - Double-barrier method - Intrauterine devices - Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - Vasectomy of partner at least 6 months prior to screening 3. Enrolled in and currently attending school at baseline and for the duration of the study period 4. Individuals with moderate stress as determined by a score of 14-26 on the PSS 5. Does not have an anxiety disorder as determined by QI assessment of the YAM-5 6. Can fluently read and speak English 7. Willing to discontinue consumption of probiotic supplements, probiotic fortified products (e.g., fortified yogurt) and fiber supplements (e.g., Metamucil, Benefiber) for the corresponding washout period indicated in Section 7.3.2 and throughout the study 8. Willingness to maintain current lifestyle habits as much as possible throughout the study including diet, exercise, sleep, and non-pharmacological therapies (e.g., meditation, yoga, breathing exercises) 9. Willingness and ability to complete questionnaires, records and diaries associated with the study and to complete all clinic visits 10. Willingness to provide biological samples (saliva, urine, stool) three times during the study 11. The child and the child's parent(s) or legal guardian(s) to provide voluntary, written, informed assent and consent, respectively, for their child to participate in the study 12. Healthy as determined by medical history as assessed by Q Exclusion Criteria: 1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study 2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients 3. Previous diagnosis or treatment of a mental health disorder or neurodevelopmental disorder, including anxiety disorders (e.g., generalized anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, seasonal affective disorder), mood disorders (e.g., major depressive disorder, bipolar disorder) or attention deficit/hyperactivity disorder within the last two years as assessed by the QI 4. Current diagnosis of a sleep disorder (e.g., obstructive sleep apnea, sleep terrors, parasomnia, restless leg syndrome), or a disorder which requires medication that may affect sleep as assessed by the QI 5. Previous diagnosis of neurological diseases (e.g., epilepsy, muscular dystrophy, cerebral palsy) assessed by the QI 6. Currently suffering from periodontitis as assessed by the QI 7. Travelled across 1 or more time zones in the last 3 weeks prior to baseline and/or is anticipating more travel during the study period 8. Current or history of any significant diseases of the gastrointestinal tract (e.g., Crohn's disease, ulcerative colitis, peptic ulcer disease) as assessed by the QI 9. Individuals with an autoimmune disease or are immune compromised 10. Use of medical cannabinoid products as assessed by the QI 11. Use of cannabinoid, tobacco or nicotine-containing products, or alcohol consumption 12. Alcohol or drug abuse within the last 12 months 13. Regular consumption of over-the-counter medications, supplements (e.g., melatonin), foods or drinks that may affect stress or sleep. The participant may be eligible after a washout period prior to their baseline visit and if they agree to discontinue use of the product throughout the study. 14. Current use of prescribed medications that may affect stress, sleep and/or mood 15. Current use of antibiotics. The participant may be eligible after a 30-day washout period prior to their baseline visit 16. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 17. Individuals who are cognitively impaired and/or unable to give informed consent 18. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic Blend
Participants will be taking 1 sachet a day, 3 billion CFU.
Placebo
Participants will be taking 1 sachet a day.

Locations

Country Name City State
Canada KGK Science Inc. London Ontario

Sponsors (2)

Lead Sponsor Collaborator
Lallemand Health Solutions KGK Science Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Incidence of pre-emergent and post-emergent adverse events (AE) and serious adverse events (SAE). This will be assessed during the 56 days intervention window and additionally during a phone call 7 days after the end of intervention (total 63 days) 63 days
Other Clinically relevant vital signs - blood pressure Systolic and diastolic blood pressure (BP) in mmHg after 56 days of supplementation. 56 days
Other Clinically relevant vital signs - heart rate Heart rate (HR) in beats/min after 56 days of supplementation. 56 days
Primary Change in stress at day 56 from baseline The difference in change from baseline in stress at Day 56 between Probiotic and Placebo measured by the Perceived Stress Scale (PSS).
The PSS is a validated and commonly used tool to measure perceived stress. Responses are rated by participants on a 5-point Likert scale. The PSS-10 has been reported to be superior to other versions of the scale and will be used in this study. The total score of PSS-10 ranges between 0-40. Scores between 0-13 are considered low stress, 14-26 are considered moderate stress, and 27-40 are considered high stress.
56 days
Secondary Change in stress at day 28 from baseline The difference in change from baseline in stress at Day 28 between Probiotic and Placebo measured by the Perceived Stress Scale (PSS) The PSS is a validated and commonly used tool to measure perceived stress. Responses are rated by participants on a 5-point Likert scale. The PSS-10 has been reported to be superior to other versions of the scale and will be used in this study. The total score of PSS-10 ranges between 0-40. Scores between 0-13 are considered low stress, 14-26 are considered moderate stress, and 27-40 are considered high stress. 28 days
Secondary Change in sleep quality from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in sleep quality as assessed by the Adolescent Sleep-Wake Scale (ASWS).
The ASWS is a 28-item scale developed to assess self-reported sleep quality in individuals 12-18 years old. The scale is comprised of five behavioral dimensions including going to bed (5 questions), falling asleep (6 questions), maintaining sleep (6 questions), reinitiating sleep (6 questions), and returning to wakefulness (5 questions). Respondents are instructed to provide responses based on the past month on a six-point Likert scale ranging from always (score=1) to never (score=6). Higher scores representing better sleep quality.
56 days
Secondary Change in daytime sleepiness from baseline The difference in change from baseline at Day 28 and 56 between Probiotic and Placebo in daytime sleepiness as assessed by the Cleveland Adolescent Sleepiness Questionnaire (CASQ) The CASQ is a tool developed to assess daytime sleepiness among adolescents aged 11-17 years old. The questionnaire is a self-reported tool comprised of 16 questions with responses ranging from "Never (0 times per month)" to "Almost every day (5 or more times per week)" and respondents are instructed to indicate their response that best represents how often it applies to them . Higher scores represent greater sleepiness. 56 days
Secondary Change in sleep-related hormones from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in sleep-related hormones as assessed by morning salivary cortisol, and nighttime salivary melatonin 56 days
Secondary Change in stress-related hormones from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in stress-related hormone as assessed by urinary free cortisol 56 days
Secondary Change in mood from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in mood as assessed by the Profile of Mood States 2nd Edition for youth (POMS2-Y) The POMS2-Y is a validated self-reported questionnaire used to measure mood state in youth 13 to 17. The short form questionnaire consists of 35 items to measure "Anger-Hostility", "Confusion-Bewilderment", "Depression-Dejection", "Tension-Anxiety", "Vigor-Activity", "Friendliness" and "Fatigue-Inertia". 56 days
Secondary Change in psychological wellbeing from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in psychological wellbeing as assessed by the Youth Anxiety Measure for DSM-5 (YAM-5).
The YAM-5 is a validated tool used to measure anxiety symptoms in children and adolescents aged 8 to 18 years based on the Diagnostic and Statistical Manual of Mental Disorders (28, 29). Respondents will be instructed to respond to each item using a four-point scale including 0=never, 1=sometimes, 2=often, and 3=always.
56 days
Secondary Change in gastrointestinal symptoms from baseline The difference in change from baseline at Days 28 and 56 between Probiotic and Placebo in gastrointestinal symptoms as assessed by the modified Gastrointestinal Symptoms Rating Scale (GSRS).
The GSRS contains 15 items, each rated on a four-point Likert scale with indications of no discomfort to very severe discomfort. The 15 item GSRS breaks down into 5 scales: abdominal pain, reflux syndrome (heartburn and acid regurgitation), diarrhea syndrome (loose stool and urgent need for defecation), indigestion syndrome (borborygmus, abdominal distension, eructation, and increased flatus), and constipation syndrome (constipation, hard stools, and feeling of incomplete evacuation). The modified GSRS has been revised to improve participant understanding and includes 14 questions with a 4-point instead of a 7-point scale for response options.
56 days
Secondary Probiotic strain retrieval in stool samples at 28 and 56 days DNA will be extracted from stool samples and real time PCR (qPCR) will be conducted to identify the presence of the probiotic strains in participants' stool samples. 56 days
Secondary Microbiome composition in stool samples Stool microbiome composition will be determined by Metagenomics analysis using shotgun metagenomic performed on samples collected at Day 28 and 56. This is explored as a secondary outcome to determine the probiotic effects on the gut microbiome composition and host-microbiome interaction. Moreover, these analyses may provide insight into the mechanisms of action of the investigational product. 56 days
Secondary Untargeted metabolomic analysis on fecal microbiome Stool metabolites will be measured by Untargeted Metabolomics analysis performed on samples collected at Day 28 and 56. This is explored as a secondary outcome to determine the probiotic effects on the metabolites identified in stool samples and may provide insight into the potential mechanisms of action of the investigational product. 56 days
See also
  Status Clinical Trial Phase
Completed NCT05130944 - Feasibility of Community Psychosocial Intervention for Women N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05881681 - A Mindfulness Approach to UA for Afro-descendants N/A
Recruiting NCT05449002 - Digital Single Session Intervention for Youth Mental Health N/A
Recruiting NCT04038190 - A Behavioral Activation Intervention Administered in a College Freshman Orientation Course Phase 2
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Active, not recruiting NCT05998161 - Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout N/A
Completed NCT03728062 - Mindfulness Meditation Versus Physical Exercise: Comparing Effects on Stress and Immunocompetence N/A
Terminated NCT04367636 - The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19 N/A
Completed NCT06405789 - The Effect of Yoga on Mindfulness and Perceived Stress N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT05245409 - Stress, EEG, ECG, and Chiropractic N/A
Completed NCT04722367 - Being Present With Art: The Impact of Mindful Engagement With Art on Awareness and Connection N/A
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Completed NCT06057883 - Effects Of A Probiotic Formulation On Stress and Skin Health in Younger Adult Females Phase 2
Completed NCT05312749 - The Effect of Web Based Progressive Muscle Relaxation Exercise on Clinical Stress and Anxiety of Nursing Students N/A
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Completed NCT05623826 - Feasibility and Efficacy of a Digital Training Intervention to Increase Reward Sensitivity- Imager N/A
Completed NCT04013451 - The Kiss of Kindness Study II N/A